Article Versions Notes

Shah M, Khalid A, Standring O, Amini N, Demyan L, Koti S, Gazzara E, Wu G, Vithlani N, DePeralta D, et al. Disparities in Immunotherapy Use Prior to First-Line Approval for Metastatic Hepatocellular Carcinoma in the United States. Onco. 2025; 5(1):6. https://doi.org/10.3390/onco5010006

Shah, Manav, Abdullah Khalid, Oliver Standring, Neda Amini, Lyudmyla Demyan, Shruti Koti, Emma Gazzara, Grace Wu, Nandan Vithlani, Danielle DePeralta, and et al. 2025. "Disparities in Immunotherapy Use Prior to First-Line Approval for Metastatic Hepatocellular Carcinoma in the United States" Onco 5, no. 1: 6. https://doi.org/10.3390/onco5010006

Shah, M., Khalid, A., Standring, O., Amini, N., Demyan, L., Koti, S., Gazzara, E., Wu, G., Vithlani, N., DePeralta, D., Gholami, S., & Weiss, M. (2025). Disparities in Immunotherapy Use Prior to First-Line Approval for Metastatic Hepatocellular Carcinoma in the United States. Onco, 5(1), 6. https://doi.org/10.3390/onco5010006